IQVIA announced on September 2, 2025 that Michael J. Fedock will succeed Ronald E. Bruehlman as Executive Vice President and Chief Financial Officer, effective February 28, 2026. The company said this transition is part of its previously announced Chief Financial Officer succession plan.

1. 01

   IQVIA announced on September 2, 2025 that Michael J. Fedock will succeed Ronald E. Bruehlman as Executive Vice President and Chief Financial Officer, effective February 28, 2026. The company said this transition is part of its previously announced Chief Financial Officer succession plan.

2. 02

   In connection with Mr. Fedock's promotion, effective February 28, 2026, his annual base salary will be $750,000, with an annual cash incentive target of 100% of his base salary, subject to the terms and conditions of the Company's annual incentive program. The company said he will be eligible to participate in annual Long Term Incentive cycles subject to the terms and conditions of the Company's 2017 Incentive and Stock Award Plan.

3. 03

   IQVIA said Ronald E. Bruehlman will retire, effective February 28, 2026, from his current role as Executive Vice President and Chief Financial Officer and transition to Senior Advisor to the CEO. The company said this ensures continuity and a seamless transition.

4. 04

   IQVIA said Fedock, age 50, has more than 25 years of experience in the healthcare industry. He joined the company in 2016 and has most recently served as Senior Vice President, Financial Planning and Analysis since April 2021. From July 2019 to April 2021, he served as Chief Financial Officer for the company's Research & Development Solutions Business Unit, and from May 2016 to July 2019, he served as Chief Financial Officer of IQVIA Laboratories.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.